ARAB JOURNAL OF GASTROENTEROLOGY, vol.17, no.2, pp.84-89, 2016 (SCI-Expanded)
Background and study aims: Infliximab (IFX) is a chimeric anti-TNF-alpha body which is effectively used in the treatment of inflammatory bowel diseases and a variety of autoimmune diseases. The effect of IFX on the healing of intestinal anastomosis has been evaluated in several studies, however with conflicting results. Furthermore, the effect of IFX on colonic anastomosis in sepsis has not been evaluated to date. In this study, we aimed to investigate whether IFX has an adverse effect on the healing process of colonic anastomosis either under normal or septic condition.